GemVax Seeks Revival Of Pancreatic Cancer Indication On ASCO Phase III Data
Executive Summary
New Phase III pancreatic cancer results for GV1001, an immunotherapeutic peptide, were presented at ASCO, which GemVax hopes will revive the drug after its conditional approval in South Korea was canceled last year.
You may also be interested in...
GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.